Blockchain Registration Transaction Record
Kairos Pharma CEO to Present at H.C. Wainwright Conference
Kairos Pharma CEO to present at H.C. Wainwright conference. Learn about ENV-105 targeting CD105 to overcome cancer drug resistance. KAPA stock update.
This news matters because Kairos Pharma's presentation at a major investment conference highlights its progress in developing ENV-105, a potential breakthrough in overcoming cancer drug resistance. For patients, this could mean more effective treatments for various cancers; for investors, it signals a promising opportunity in the oncology space. The company's focus on targeting CD105 addresses a critical unmet need in cancer therapy, making this announcement significant for both the medical community and those interested in biotech investments.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x47e2056c739ba3de81a9138d62a8cf0ee3f58fd9b8767795597cecd19d0e566a |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | archsgu4-733fab8c9f272ad21203dbd4af1dca18 |